Articles

Treatment of poor-prognosis germ-cell tumours

BJMO - 2019, issue Special, march 2019

Prof. dr. Karim Fizazi

Summary

For several decades the standard of care in patients with poor-risk non-seminomatous germ-cell tumours (NSGCT) has been 4 cycles of bleomycin, etoposide and cisplatin (BEP). However, there are data to support that in patients with an unfavourable decline in tumour markers after a first cycle of BEP, a high-dose chemotherapy regimen should become the standard of care. Dr. Fizazi also insisted on the importance of centralisation of care and provided some new insights for the treatment of patients with germ-cell tumours (GCT) following a relapse.

Read more

Navigating the evolving therapeutic landscape in M1 prostate cancer

BJMO - 2019, issue Special, march 2019

Prof. dr. Karim Fizazi

Summary

More than half of the patients who ultimately die from prostate cancer (PCa) are patients who already have metastases at the time of their diagnosis (de novo metastatic patients).1 Until recently, the treatment of M1 PCa patients consisted of androgen deprivation therapy (ADT). In recent years this treatment paradigm changed following the publication of convincing clinical data demonstrating a significant survival advantage of adding docetaxel or abiraterone acetate (AA) to ADT.2–8 During BMUC 2019, Prof. dr. Karim Fizazi (Institut Gustave Roussy, Paris, France) gave an overview of the latest developments in treatment of M1 PCa patients.

Read more
X